Subcutaneous (SC) Daratumumab (DARA) in Combination with Standard Multiple Myeloma (MM) Treatment Regimens: an Open-label, Multicenter Phase 2 Study (PLEIADES)
Clinical Lymphoma Myeloma & Leukemia（2019）
Key words
CD38,daratumumab,Multiple myeloma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined